The smart money back then was that the large traditional pharmaceutical firms had a model, had a mindset, and had a whole set of processes and infrastructure and people who grew up and got promoted thinking that way, would never be able to adapt.

And that led to investors coming in. And this was really the the the accelerant for what we know today

as the modern venture capital industry well I'm not sure what you were up to last Sunday, but you set another records for downloads for the INSDEC London podcast on a single day.

And we're all heading into a month of lockdown again here in the UK.

And I guess wherever you are listening from, you two are going to be restricted on what you get up to.

But the great thing about audio, of course, is you can at least get outside for a bit, plug in

and still keep up with what's going on in the world. And with face-to-face events not going to be

happening for at least another few months, we're getting our creative juices flowing here in

Steck, London to keep our community engaged

and connected into 2021.

Matthew Grant here and this week I am talking to Paul Mang.

Paul currently heads up guide-wise analytical and data business, but his career is wide-ranging

and he's invested in and mentored start-ups and scale-ups in a variety of industries.

Paul's got some great observations, including lessons from biotech for insuretech, and it's worth staying on to the end to hear his

predictions for what's coming up next. And if you haven't already discovered what we're up to at

Instech London or we'd like to become part of our community, then do take a look at the website

www.instech..london.

We're in regular contact now with over 15,000 people around the world

from insurance and technology, big and small, new and old.

And you'll also find our editor highlights of this interview on the website to read and share.

And now back to Paul.

Paul is fantastic to be talking to you today. You've got so much experience. It's sort of hard to know where to start.

...